Thomas Craig Sells 8,500 Shares of Idexx Laboratories Inc. (IDXX) Stock
Idexx Laboratories Inc. (NASDAQ:IDXX) Director Thomas Craig sold 8,500 shares of the company’s stock in a transaction on Wednesday, November 23rd. The shares were sold at an average price of $120.06, for a total value of $1,020,510.00. Following the completion of the sale, the director now owns 32,783 shares in the company, valued at $3,935,926.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Idexx Laboratories Inc. (NASDAQ:IDXX) opened at 120.34 on Wednesday. The company’s 50-day moving average price is $111.46 and its 200 day moving average price is $103.18. The stock has a market capitalization of $10.79 billion, a P/E ratio of 51.25 and a beta of 0.48. Idexx Laboratories Inc. has a 52-week low of $63.48 and a 52-week high of $120.80.
Idexx Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, November 1st. The company reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.60 by $0.02. The firm earned $448.30 million during the quarter, compared to analysts’ expectations of $448.60 million. Idexx Laboratories had a negative return on equity of 788.91% and a net margin of 12.36%. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.48 earnings per share. On average, equities research analysts anticipate that Idexx Laboratories Inc. will post $2.38 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Thomas Craig Sells 8,500 Shares of Idexx Laboratories Inc. (IDXX) Stock” was published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this news story on another site, it was stolen and reposted in violation of United States and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2016/11/30/thomas-craig-sells-8500-shares-of-idexx-laboratories-inc-idxx-stock.html.
Several brokerages have recently issued reports on IDXX. Canaccord Genuity set a $125.00 price objective on Idexx Laboratories and gave the company a “buy” rating in a research report on Saturday, October 15th. Stifel Nicolaus restated a “buy” rating and issued a $120.00 price objective (up from $92.00) on shares of Idexx Laboratories in a research report on Wednesday, August 3rd. Northcoast Research upgraded Idexx Laboratories from a “sell” rating to a “neutral” rating in a research report on Wednesday, August 3rd. Zacks Investment Research upgraded Idexx Laboratories from a “hold” rating to a “buy” rating and set a $121.00 price objective on the stock in a research report on Thursday, August 4th. Finally, Bank of America Corp. restated a “neutral” rating on shares of Idexx Laboratories in a research report on Thursday, September 29th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Idexx Laboratories presently has a consensus rating of “Buy” and an average target price of $105.20.
Hedge funds have recently added to or reduced their stakes in the stock. ETRADE Capital Management LLC boosted its stake in Idexx Laboratories by 47.0% in the third quarter. ETRADE Capital Management LLC now owns 5,232 shares of the company’s stock worth $590,000 after buying an additional 1,672 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Idexx Laboratories by 0.3% in the third quarter. Price T Rowe Associates Inc. MD now owns 4,546,191 shares of the company’s stock worth $512,492,000 after buying an additional 14,294 shares during the last quarter. Cornerstone Capital Management Holdings LLC. boosted its stake in Idexx Laboratories by 3,513.9% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 69,639 shares of the company’s stock worth $7,849,000 after buying an additional 67,712 shares during the last quarter. Balentine LLC purchased a new stake in Idexx Laboratories during the third quarter worth about $601,000. Finally, Peloton Wealth Strategists purchased a new stake in Idexx Laboratories during the third quarter worth about $1,945,000. 90.84% of the stock is owned by hedge funds and other institutional investors.
Idexx Laboratories Company Profile
Receive News & Stock Ratings for Idexx Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idexx Laboratories Inc. and related stocks with our FREE daily email newsletter.